QQQ   273.53 (+2.35%)
AAPL   142.45 (+3.08%)
MSFT   240.74 (+3.37%)
META   138.61 (+2.16%)
GOOGL   98.64 (+3.13%)
AMZN   115.88 (+2.55%)
TSLA   242.40 (-8.61%)
NVDA   125.12 (+3.07%)
NIO   15.49 (-1.78%)
BABA   80.45 (+0.58%)
AMD   66.11 (+4.34%)
T   15.90 (+3.65%)
MU   51.72 (+3.23%)
CGC   2.91 (+6.59%)
F   11.47 (+2.41%)
GE   63.60 (+2.73%)
DIS   97.13 (+2.97%)
AMC   6.88 (-1.29%)
PYPL   87.18 (+1.29%)
PFE   44.14 (+0.87%)
NFLX   239.04 (+1.53%)
QQQ   273.53 (+2.35%)
AAPL   142.45 (+3.08%)
MSFT   240.74 (+3.37%)
META   138.61 (+2.16%)
GOOGL   98.64 (+3.13%)
AMZN   115.88 (+2.55%)
TSLA   242.40 (-8.61%)
NVDA   125.12 (+3.07%)
NIO   15.49 (-1.78%)
BABA   80.45 (+0.58%)
AMD   66.11 (+4.34%)
T   15.90 (+3.65%)
MU   51.72 (+3.23%)
CGC   2.91 (+6.59%)
F   11.47 (+2.41%)
GE   63.60 (+2.73%)
DIS   97.13 (+2.97%)
AMC   6.88 (-1.29%)
PYPL   87.18 (+1.29%)
PFE   44.14 (+0.87%)
NFLX   239.04 (+1.53%)
QQQ   273.53 (+2.35%)
AAPL   142.45 (+3.08%)
MSFT   240.74 (+3.37%)
META   138.61 (+2.16%)
GOOGL   98.64 (+3.13%)
AMZN   115.88 (+2.55%)
TSLA   242.40 (-8.61%)
NVDA   125.12 (+3.07%)
NIO   15.49 (-1.78%)
BABA   80.45 (+0.58%)
AMD   66.11 (+4.34%)
T   15.90 (+3.65%)
MU   51.72 (+3.23%)
CGC   2.91 (+6.59%)
F   11.47 (+2.41%)
GE   63.60 (+2.73%)
DIS   97.13 (+2.97%)
AMC   6.88 (-1.29%)
PYPL   87.18 (+1.29%)
PFE   44.14 (+0.87%)
NFLX   239.04 (+1.53%)
QQQ   273.53 (+2.35%)
AAPL   142.45 (+3.08%)
MSFT   240.74 (+3.37%)
META   138.61 (+2.16%)
GOOGL   98.64 (+3.13%)
AMZN   115.88 (+2.55%)
TSLA   242.40 (-8.61%)
NVDA   125.12 (+3.07%)
NIO   15.49 (-1.78%)
BABA   80.45 (+0.58%)
AMD   66.11 (+4.34%)
T   15.90 (+3.65%)
MU   51.72 (+3.23%)
CGC   2.91 (+6.59%)
F   11.47 (+2.41%)
GE   63.60 (+2.73%)
DIS   97.13 (+2.97%)
AMC   6.88 (-1.29%)
PYPL   87.18 (+1.29%)
PFE   44.14 (+0.87%)
NFLX   239.04 (+1.53%)
NASDAQ:GH

Guardant Health - GH Price Target & Analyst Ratings

$54.83
+1.00 (+1.86%)
(As of 10/3/2022 12:00 AM ET)
Add
Compare
Today's Range
$52.30
$55.53
50-Day Range
$47.14
$61.00
52-Week Range
$27.65
$121.26
Volume
1.09 million shs
Average Volume
1.18 million shs
Market Capitalization
$5.60 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$115.75

Guardant Health Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 13 Analyst Ratings

Consensus Analyst Price Target

$115.75
111.11% Upside
High Prediction$165.00
Average Prediction$115.75
Low Prediction$65.00
TypeCurrent
10/3/21 to 10/3/22
1 Month Ago
9/3/21 to 9/3/22
3 Months Ago
7/5/21 to 7/5/22
1 Year Ago
10/3/20 to 10/3/21
Consensus Rating
Buy
Buy
Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
13 Buy rating(s)
13 Buy rating(s)
10 Buy rating(s)
10 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$115.75$115.75$126.90$167.50
Predicted Upside111.11% Upside90.82% Upside103.48% Upside23.56% Upside
Get Guardant Health Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for GH and its competitors with MarketBeat's FREE daily newsletter.


GH Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Guardant Health Stock vs. The Competition

TypeGuardant HealthMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.68
2.49
Consensus RatingBuyBuyHold
Predicted Upside111.11% Upside1,084.07% Upside31.94% Upside
News Sentiment RatingPositive News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
235
70.36%
Underperform Votes
99
29.64%
Avg. Outperform Votes
165
66.53%
Avg. Underperform Votes
83
33.47%
Avg. Outperform Votes
852
68.38%
Avg. Underperform Votes
394
31.62%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/24/2022Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$80.00+58.89%
8/8/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$90.00 ➝ $80.00+40.92%
8/8/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$85.00 ➝ $80.00+40.92%
8/1/2022OTR Global
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradePositive
6/2/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$65.00+56.82%
5/6/2022Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$120.00 ➝ $100.00+97.16%
2/24/2022Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$180.00 ➝ $165.00+178.06%
2/24/2022Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$160.00 ➝ $130.00+119.08%
2/24/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$170.00 ➝ $110.00+84.47%
2/24/2022Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$150.00 ➝ $115.00+92.86%
2/24/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$170.00 ➝ $140.00+134.78%
11/5/2021BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Sung Ji Nam
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$159.00+44.30%
6/15/2021Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform
5/27/2021William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy
12/16/2020Smith Barney Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$145.00 ➝ $155.00+26.79%
11/6/2020JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$120.00 ➝ $135.00+14.97%
2/21/2020Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$103.00+17.82%
(Data available from 10/3/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












GH Price Target - Frequently Asked Questions

What is Guardant Health's consensus rating and price target?

According to the issued ratings of 13 analysts in the last year, the consensus rating for Guardant Health stock is Buy based on the current 13 buy ratings for GH. The average twelve-month price prediction for Guardant Health is $115.75 with a high price target of $165.00 and a low price target of $65.00. Learn more on GH's analyst rating history.

Do Wall Street analysts like Guardant Health more than its competitors?

Analysts like Guardant Health more than other Medical companies. The consensus rating score for Guardant Health is 3.00 while the average consensus rating score for medical companies is 2.68. Learn more on how GH compares to other companies.

Do MarketBeat users like Guardant Health more than its competitors?

MarketBeat users like Guardant Health more than other Medical companies. 70.36% of MarketBeat users gave Guardant Health an outperform vote while medical companies recieve an average of 66.53% outperform votes by MarketBeat users.

Is Guardant Health being downgraded by Wall Street analysts?

Over the previous 90 days, Guardant Health's stock had 1 downgrade by analysts.

Does Guardant Health's stock price have much upside?

According to analysts, Guardant Health's stock has a predicted upside of 90.82% based on their 12-month price targets.

What analysts cover Guardant Health?

Guardant Health has been rated by Credit Suisse Group, Morgan Stanley, OTR Global, and The Goldman Sachs Group in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:GH) was last updated on 10/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.